Oncology Medical News about elimination of HPV16 infection;Praneem polyherbal tablet;early cervical intraepithelial lesions

Become a Member Today!
Register

Most Viewed Abstracts

1. Report Shows Shift in Starting Salaries for Physicians

2. Recommendations on the use of 18F-FDG PET in oncology

3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials

4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer

5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ

Your Article Summary

See Latest Articles

(Click the title below to leave the MDLinx Network and go to the Journal's Website)

Elimination of high-risk human papillomavirus type HPV16 infection by Praneem polyherbal tablet in women with early cervical intraepithelial lesions
Journal of Cancer Research & Clinical Oncology, 06/17/09

Shukla S et al. - In a trial to evaluate potential anti-HPV activity of Praneem in women infected with high-risk HPV type 16 (HPV16), it was reported that a 30-day intra-vaginal application of the Praneem can result in elimination of HPV infection from the uterine cervix.

Methods

20 women molecularly diagnosed positive for HPV16 infection without or with low grade squamous intraepithelial lesion (LSIL) or inflammation were assigned to receive intra-vaginal, topical application of either Praneem tablet or placebo for 30 days excluding the days of menstrual period.
They were evaluated for persistence of HPV infection using HPV L1 consensus and HPV16-specific PCR as primary outcome.

Results

1 course of Praneem treatment resulted in elimination of HPV in 6 of 10 (60%) cases.
A repeat treatment of 4 pts with persisting HPV infection resulted in clearance of HPV in 2 additional cases resulting in an overall 80% clearance of HPV16 as against a spontaneous clearance of 10% (1/10) in the placebo arm.
Elimination of HPV DNA was found to be accompanied by marked improvement in clinical symptoms and cytological abnormalities of Praneem-treated pts.

<< Previous
Frequent loss of endothelin-3 (EDN3) expression due to epigenetic...

Next >>
Phase I study of eribulin mesylate administered once every 21...